Premium
Pharmacokinetic studies of cholinesterase inhibitors
Author(s) -
Johansson M.,
Nordberg A.
Publication year - 1993
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1993.tb04249.x
Subject(s) - tacrine , cholinesterase , pharmacokinetics , physostigmine , pharmacology , volume of distribution , metabolite , donepezil , chemistry , cerebrospinal fluid , distribution (mathematics) , medicine , dementia , acetylcholinesterase , biochemistry , acetylcholine , enzyme , mathematical analysis , mathematics , disease
The pharmacokinetic of some centrally acting cholinesterase inhibitors that have been used to improve memory in patients with dementia of Alzheimer's type, was compared. The original compound in this class, physostigmine has an elimination half‐life of 20–30 min. Galanthamine, tacrine and the metabolite 1‐hydroxytacrine (velnacrine) have longer elimination half‐lives of 1.6–6 hours mainly due to a larger volume of distribution. The concentration of tacrine in the cerebrospinal fluid (CSF) was less than the average plasma concentration in the dosing interval; a ratio of 0.74. The concentration of 1‐hydroxytacrine and other metabolites of tacrine in the CSF were higher than the average concentrations of the compounds in plasma.